Marijn E. Dekkers - Nov 3, 2022 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Director
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Nov 3, 2022
Transactions value $
-$438,925
Form type
4
Date filed
11/7/2022, 08:34 PM
Previous filing
Jun 16, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Sale -$439K -171K -7.82% $2.56 2.02M Nov 3, 2022 Direct F1
holding DNA Class A Common Stock 5.78M Nov 3, 2022 By Novalis LifeSciences Investments I, L.P. F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the Reporting Person pursuant to a 10b5-1 plan to cover such individual's estimated tax withholding obligations in connection with the vesting of restricted stock units.
F2 The reporting person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.